| Backgroud and objectiveSmall cell lung cancer (SCLC) accounts for 15% to 20% of lung cancers. SCLC is the most aggressive form of lung cancer. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, the liver, and the bones. At present a number of studies have shown that chemotherapy, radiotherapy and surgery combined therapy significantly improved the prognosis of small cell lung cancer. This study explores the relevance of small-cell lung cancer prognostic factors and the survival of different treatment methods.MethodsBy the use of the SAS 9.2 for statistical analysis, Kaplan-Meier method for calculating survival rate, Log-rank non-parametric test, COX proportional hazard model for multivariate survival analysis, the survival rate and prognostic factors of the fifty six cases of small cell lung cancer are analyzed. ResultsAll the 56 patients had complete follow-up data. The median survival time(MST) of all the patients is 19 months, one-year survival rate was 74.61%,2-year survival rate is 32.70%. Univariate analysis indicated that age, stage, operation and radiotherapy combining with chemotherapy significantly influenced survival in SCLC. While neither gender nor smoking influences survival in SCLC. Multivariate analysis suggested that age, clincal stage and radiotherapy combining with chemotherapy are the key prognostic factors of survival. Patients with refractory or relapsed small-cell lung cancer can get better efficiency, on condition that they select second-line chemotherapy..ConclusionFor limited stage patients, comprehensive Treatment with chemotherapy, radiotherapy and surgery reflects better efficacy. And for broad stage patients, in addition to chemotherapy, local radiotherapy improves the prognosis of metastatic; regimens containing irinotecan for second-line treatment is an effective treatment. Patients with refractory or relapsed small-cell lung cancer who select second-line chemotherapy can get better efficiency.
|
PDF Full Text Request